Pharvaris N.V.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Berndt Modig
- Full Time Employees
- 148
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Grafenauweg 8 Zug ZH Switzerland 6300
- IPO Date
- Feb 4, 2021
- CIK
- 0001830487
- Website
- pharvaris.com
- Similar Companies
- Business
- Pharvaris N.V. (Nasdaq: PHVS) is a late-stage biopharmaceutical company focused on developing novel oral bradykinin B2 receptor antagonists for the treatment and prevention of bradykinin-mediated diseases, including hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH). Founded in 2015 and headquartered in Zug, Switzerland, with operations in the Netherlands and the United States, the company advances deucrictibant as its lead candidate: PHVS416, an immediate-release softgel capsule for on-demand HAE attack treatment; and PHVS719, an extended-release tablet for prophylactic use. Its pipeline targets patients aged 12 and older across global markets, with pivotal Phase 3 trials conducted in 24 countries. In December 2025, Pharvaris announced positive topline results from the RAPIDe-3 Phase 3 trial of deucrictibant immediate-release capsules, meeting the primary endpoint of median time to onset of symptom relief at 1.28 hours versus over 12 hours for placebo, and achieving all 11 secondary endpoints including rapid symptom resolution; topline data from the ongoing CHAPTER-3 prophylactic trial is expected in the second half of 2026, with a U.S. New Drug Application submission planned for the first half of 2026. Earlier in July 2025, the company completed an upsized $175 million underwritten public offering of ordinary shares to fund late-stage clinical programs, U.S. commercialization efforts including sales and marketing team hiring, and general corporate purposes.
Company News
Pharvaris Presents Translational, Nonclinical, and Clinical Data at Bradykinin Symposium 2026
BlackRock Inc. Makes New Investment in Pharvaris N.V. $PHVS
5AM Venture Management LLC Makes New $27.58 Billion Investment in Pharvaris N.V. $PHVS
Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update
Assessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in Immunology
Pharvaris: One Molecule Could Reshape Both Sides Of HAE Treatment
Wall Street Analysts Think Pharvaris (PHVS) Could Surge 43.03%: Read This Before Placing a Bet
After a 96% 1-Year Run, This Director Sold 37,600 PHVS Shares for $1.3 Million. Is the Rally Over?
Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema
Here's Why Pharvaris N.V. (PHVS) is a Great Momentum Stock to Buy
Wall Street Analysts Believe Pharvaris (PHVS) Could Rally 36.16%: Here's is How to Trade
Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks
Data Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026
Pharvaris Announces Annual General Meeting of Shareholders
Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026
Pharvaris N.V. (PHVS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Pharvaris Reports First Quarter 2026 Financial Results and Provides Business Update
Pharvaris Chief Medical Officer Sells 14,000 Shares for $427,000
Pharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters' Option to Purchase Additional Shares
Pharvaris Announces Pricing of $115 Million Underwritten Offering of Ordinary Shares